Quantitative brain imaging biomarkers now play a central role in clinical trials for AD, as they may permit a more direct assessment of the effects of a therapy on brain function, amyloid load, and rate of neurodegeneration. Such information complements clinical and cognitive data points to provide a more complete picture of an intervention's putative disease-modifying effects. Further, clinical brain imaging and central clinical overread may be required for monitoring patient safety during a trial. However, the complexity of imaging data requires ready access to specialized neuroimaging expertise to assist in developing and maintaining state-of-the-art approaches in study design as well as data management, analysis, and sharing. No single institution houses such a wide array of expertise, and the rapid evolution of the field calls for an organizational structure that allows project leaders flexibility in selecting best available design and analysis approaches, while maintaining consistency through centralized data upload and management.
The overarching objective of the imaging core is to provide the infrastructure necessary for collection, management, and analysis of PET and MRI biomarkers in ADCS clinical trials and assist in widely sharing these data upon trial completion.
|Besser, Lilah; Kukull, Walter; Knopman, David S et al. (2018) Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 32:351-358|
|Jacobs, Heidi I L; Hedden, Trey; Schultz, Aaron P et al. (2018) Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci 21:424-431|
|Buckley, Rachel F; Mormino, Elizabeth C; Amariglio, Rebecca E et al. (2018) Sex, amyloid, and APOE ?4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimers Dement 14:1193-1203|
|Jacobs, Diane M; Ard, M Colin; Salmon, David P et al. (2017) Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimers Dement (N Y) 3:531-535|
|Marquié, Marta; Verwer, Eline E; Meltzer, Avery C et al. (2017) Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. Acta Neuropathol Commun 5:75|
|Dekhtyar, Maria; Papp, Kathryn V; Buckley, Rachel et al. (2017) Neuroimaging markers associated with maintenance of optimal memory performance in late-life. Neuropsychologia 100:164-170|
|Schultz, Aaron P; Chhatwal, Jasmeer P; Hedden, Trey et al. (2017) Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals. J Neurosci 37:4323-4331|
|Vannini, Patrizia; Hanseeuw, Bernard; Munro, Catherine E et al. (2017) Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging. Neuroimage Clin 15:408-414|
|Donohue, Michael C; Sperling, Reisa A; Petersen, Ronald et al. (2017) Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA 317:2305-2316|
|LaPoint, Molly R; Chhatwal, Jasmeer P; Sepulcre, Jorge et al. (2017) The association between tau PET and retrospective cortical thinning in clinically normal elderly. Neuroimage 157:612-622|
Showing the most recent 10 out of 490 publications